<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161417</url>
  </required_header>
  <id_info>
    <org_study_id>GN17on293</org_study_id>
    <nct_id>NCT04161417</nct_id>
  </id_info>
  <brief_title>Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer</brief_title>
  <official_title>Precision-Panc Master Protocol: Personalising Treatment For Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Judith Dixon-Hughes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Glasgow</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Precision-Panc Master Protocol is a &quot;portal&quot; protocol for patients with known or
      suspected pancreatic cancer to be accrued through multiple centres in the UK, with the option
      of being subsequently enrolled into PRIMUS (Pancreatic canceR Individualised Multi-arm
      Umbrella Studies) examining different treatment regimens and/or biomarker development.
      Eligible patients will undergo tumour biopsy and blood collection prospectively for molecular
      profiling at a central laboratory and the results may be used to inform enrolment to PRIMUS
      studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study is seen as interventional as patients may have more tissue taken at diagnositic biopsy than if they were not part of the trial or may have an extra biopsy if there is not enough material available from their diagnostic biopsy.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proving that patients with pancreatic cancer can have their tissue molecularly assessed and be followed up in a clinical trial setting</measure>
    <time_frame>At end of study (5 years)</time_frame>
    <description>The number of patients screened and registered to the master protocol will be recorded. The number of patients who we are able to molecular assess will be recorded and all patients will be followed up in the master protocol until death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of registration until date of death from any cause, assessed up to 5 years</time_frame>
    <description>To assess the overall survival (OS) in patients enrolled in Precision-Panc and relate this to molecular profile information.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with biopsy related adverse events as assesed by CTCAE v4.03</measure>
    <time_frame>At time of biopsy, usually within one week of screening</time_frame>
    <description>To assess the safety of obtaining tumour biopsies suitable for molecular profiling within a standard patient treatment pathway.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>At time of progression (this is estimated at around 6-9 months for this group of patients)</time_frame>
    <description>To assess the progression-free survival (PFS) in patients enrolled in Precision-Panc and relate this to molecular profile information</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Neoplasms Pancreatic</condition>
  <arm_group>
    <arm_group_label>Biopsy Material Required for Registration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The Precision-Panc Master Protocol aims to recruit, consent and screen patients with pancreatic cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling</intervention_name>
    <description>Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling. This will enable patient enrolment into a currently available PRIMUS study</description>
    <arm_group_label>Biopsy Material Required for Registration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (age &gt;16 years).

          -  Either:

               -  Presence of a hypodense pancreatic mass highly suspicious of primary pancreatic
                  cancer with or without distant metastasis as assessed by a Pancreatic
                  Multi-Disciplinary Team (MDT).

        Or

        o Histologically or cytologically confirmed pancreatic ductal adenocarcinoma and its
        variants.

          -  Patient is willing and able to undergo additional tumour biopsy (from the primary or a
             metastatic site) aimed at obtaining sufficient tissue for molecular profiling if this
             is required.

          -  Patient is deemed suitable to receive chemotherapy and/or radiotherapy, and/or surgery
             pending stage of disease at presentation.

          -  Patient is deemed potentially eligible for a currently open PRIMUS study

          -  Patient has signed informed consent for screening research tumour biopsy (Consent 1).

          -  Patient has signed informed consent for Precision-Panc Master Protocol molecular
             profiling (Consent 2).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Chang</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Valle</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manchester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judith Dixon-Hughes</last_name>
    <phone>01413302718</phone>
    <email>judith.dixon@glasgow.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Cheyne</last_name>
      <email>angela.cheyne@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Bassam Alkari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Ireland Cancer Centre</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Shannon</last_name>
      <email>Marie.Shannon@belfasttrust.hscni.net</email>
    </contact>
    <investigator>
      <last_name>Richard Turkington</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catia Guerreiro</last_name>
      <email>Catia.Guerreiro@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Yuk Ting Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Milne</last_name>
      <email>rebecca.milne@rbch.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Tamas Hickish</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Delogu</last_name>
      <email>Francesca.Delogu@UHBristol.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Stephen Falk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Wong</last_name>
      <email>emma.wong@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Bristi Basu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Cottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magda Kolodziej</last_name>
      <email>magdalena.kolodziej@hey.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anthony Maraveyas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Cumming</last_name>
      <email>helencumming@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Asa Dahle-Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Thornton</last_name>
      <email>Susan.Thornton@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Colin McKay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James's Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Crossley</last_name>
      <email>anne.crossley1@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Andrew Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Stimpson</last_name>
      <email>sarah.stimpson@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Harpreet Wasan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ane Zamalloa</last_name>
      <email>ane.zamalloa@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Andreas Prachalias</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tahmin Ahmed</last_name>
      <email>tahmin.ahmed1@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Fusai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Crux</last_name>
      <email>Richard.Crux@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Naureen Starling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Varro</last_name>
      <email>robert.varro@stgeorges.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anna-Mary Young</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emen Mohamad</last_name>
      <email>emen.mohamad@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Daniel Hochhauser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Panes</last_name>
      <email>Alice.Panes@mft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Derek O'Reilly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie, Manchester</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Staiger</last_name>
      <email>Helen.Staiger@christie.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Juan Valle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmin Snowdon</last_name>
      <email>Jasmin.Snowdon@nuth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Kofi Oppong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerri Jenkins</last_name>
      <email>Kerri.Jenkins@nuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Arvind Arora</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Cousins</last_name>
      <email>trialadministrator08@oncology.ox.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Kinnari Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pool Hospital</name>
      <address>
        <city>Poole</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Barnsley</last_name>
      <email>Rachel.Barnsley@poole.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Lachlan Ayres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weston Park</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyper Allan</last_name>
      <email>c.allan@sheffield.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Jonathan Wadsley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liane Armstrong</last_name>
      <email>liane.armstrong@uhs.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Andrew Bateman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Albert Edward Infirmary</name>
      <address>
        <city>Wigan</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Devereaux</last_name>
      <email>Louise.Devereaux@wwl.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Richard Keld</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Glasgow</investigator_affiliation>
    <investigator_full_name>Judith Dixon-Hughes</investigator_full_name>
    <investigator_title>Project Manager</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>When the clinical study report at end of study is complete all data will be available to other researchers. Researchers should contact study Trial Management Group for access. All genomic data will be made available through ICGC ARGO.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>On study completion</ipd_time_frame>
    <ipd_access_criteria>Request to TMG</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

